Abcentra Kicks Off Phase 2b Trial for Game-Changing Heart Inflammation Drug

Heart attacks don’t just end when you leave the hospital. For many, the inflammation that triggered the attack keeps smoldering—quietly setting the stage for another one. Abcentra believes it’s time to put that fire out.

The Milestone: First Patient Dosed in FORTIFY Trial

Abcentra LLC just dosed the first patient in FORTIFY, a Phase 2b trial testing orticumab—their experimental therapy for cardiovascular inflammation after type 1 myocardial infarction (MI).

Why this matters:

• Cardiovascular inflammation is a root cause of recurrent heart attacks.
• Current treatments focus on cholesterol but don’t fully address plaque inflammation.
• Orticumab targets the problem locally inside atherosclerotic plaques.

How the FORTIFY Study Works?

Study name: FORTIFY (NCT06927739) – Focused Orticumab Research for Treating Inflammation in Coronary Arteries

Design highlights:

• Multi-center, randomized, placebo-controlled, double-blind
• 40 sites in the US, UK, and Europe
• 240 patients with prior type 1 MI and high coronary inflammation
• Two orticumab dose arms vs. two placebo arms
• Treatment: 24 weeks

Primary goal:

• Reduce Fat Attenuation Index (FAI) scores at Week 24 using coronary CT angiography (CCTA).

Why FAI Scoring Is a Big Deal

FAI is an advanced imaging biomarker. It offers a “window” into coronary artery inflammation—a key predictor of major adverse cardiovascular events.

Dr. Peter Libby, board member and cardiovascular researcher, explains:

“By using cutting-edge imaging, we can see if orticumab truly reduces the inflammation driving heart attack risk.”

What Makes Orticumab Different

Orticumab is a monoclonal antibody targeting oxidized LDL. That means it works differently than standard cholesterol-lowering drugs:

• Goes beyond lowering LDL numbers.
• Directly inhibits inflammation inside vulnerable plaques.
• Could help prevent recurring heart attacks.

CEO Christopher Farina says:

“We’re aiming to significantly reduce cardiovascular risk on top of current care by targeting inflammation at the source.”

The Bigger Picture

Cardiovascular disease remains the world’s leading killer. If FORTIFY proves successful, orticumab could:

• Redefine secondary prevention in heart disease.
• Give doctors a targeted way to calm dangerous plaque inflammation.
• Complement existing cholesterol-lowering strategies.

Chairman John Farina calls the trial:

“A major step forward for the cardiovascular field and a potentially transformative therapy.”

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!